Important Japanese Clinical Trial in Recurrent Head & Neck Cancer
Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan, that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT in Japanese patients with recurrent Head & Neck cancer after radiotherapy. - Click here if this is your press release! - eTurboNews | Trends | Travel News
Source: eturbonews.com
